Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) has
been the only proven therapy for acute ischemic stroke (AIS) for almost 20 years. Whether IV
t-PA prior to endovascular clot retrieval is beneficial for AIS patients with a proximal
vessel occlusion in the anterior circulation has currently become a matter of debate and is a
relevant unanswered question in clinical practice.
The main objective is to determine whether subjects experiencing an AIS due to large
intracranial vessel occlusion in the anterior circulation will have non-inferior functional
outcome at 90 days when treated with direct mechanical thrombectomy (MT) compared to subjects
treated with combined IV t-PA and MT.
The secondary objectives are to study causes of mortality, dependency and quality of life in
these AIS patients.